CN101824400A - 一种放大增殖抗原特异性t细胞的方法 - Google Patents
一种放大增殖抗原特异性t细胞的方法 Download PDFInfo
- Publication number
- CN101824400A CN101824400A CN200910079259A CN200910079259A CN101824400A CN 101824400 A CN101824400 A CN 101824400A CN 200910079259 A CN200910079259 A CN 200910079259A CN 200910079259 A CN200910079259 A CN 200910079259A CN 101824400 A CN101824400 A CN 101824400A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- immunogen
- specific
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 130
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 11
- 230000002163 immunogen Effects 0.000 claims abstract description 43
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 108091007433 antigens Proteins 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 101000588258 Taenia solium Paramyosin Proteins 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 113
- 230000036039 immunity Effects 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 claims description 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 18
- 206010052428 Wound Diseases 0.000 claims description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 210000002865 immune cell Anatomy 0.000 abstract description 5
- 230000001900 immune effect Effects 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 description 51
- 241000712461 unidentified influenza virus Species 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 201000001441 melanoma Diseases 0.000 description 21
- 101800001271 Surface protein Proteins 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 10
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 238000011830 transgenic mouse model Methods 0.000 description 10
- 229930192392 Mitomycin Natural products 0.000 description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 9
- 229960004857 mitomycin Drugs 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000975 dye Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000007192 gp100 Melanoma Antigen Human genes 0.000 description 4
- 108010008486 gp100 Melanoma Antigen Proteins 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 3
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 3
- 229930191564 Monensin Natural products 0.000 description 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010038997 Retroviral infections Diseases 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229960005358 monensin Drugs 0.000 description 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 238000011794 NU/NU nude mouse Methods 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Description
Claims (5)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100792599A CN101824400B (zh) | 2009-03-05 | 2009-03-05 | 一种放大增殖抗原特异性t细胞的方法 |
PCT/CN2009/000481 WO2010099637A1 (zh) | 2009-03-05 | 2009-04-30 | 增殖抗原特异性t细胞的方法 |
US13/254,039 US9080152B2 (en) | 2009-03-05 | 2009-04-30 | Methods for proliferation of antigen-specific T cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100792599A CN101824400B (zh) | 2009-03-05 | 2009-03-05 | 一种放大增殖抗原特异性t细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101824400A true CN101824400A (zh) | 2010-09-08 |
CN101824400B CN101824400B (zh) | 2012-08-08 |
Family
ID=42688565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100792599A Expired - Fee Related CN101824400B (zh) | 2009-03-05 | 2009-03-05 | 一种放大增殖抗原特异性t细胞的方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9080152B2 (zh) |
CN (1) | CN101824400B (zh) |
WO (1) | WO2010099637A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102662054A (zh) * | 2012-05-10 | 2012-09-12 | 东南大学 | 一种同步检测特异性胸腺依赖性淋巴细胞数量和功能的方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012351347B2 (en) | 2011-12-12 | 2016-05-19 | Baylor College Of Medicine | Process of expanding T cells |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
EP3444278A1 (en) * | 2013-02-26 | 2019-02-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
PT3456339T (pt) | 2013-08-05 | 2021-12-09 | Immatics Biotechnologies Gmbh | Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc |
JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
JP7357613B2 (ja) * | 2017-11-06 | 2023-10-06 | ラディック インスティテュート フォア キャンサー リサーチ リミテッド | リンパ球の拡大方法 |
CN110819591A (zh) * | 2018-08-07 | 2020-02-21 | 上海恒润达生生物科技有限公司 | 一种cart细胞制备方法 |
CN113564116B (zh) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ce的制备方法 |
CN116785415B (zh) * | 2023-05-04 | 2024-03-22 | 北京百普赛斯生物科技股份有限公司 | 一种特异性针对免疫细胞激活/增殖刺激的产品、制备及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030148982A1 (en) * | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
US20050009180A1 (en) * | 2001-12-10 | 2005-01-13 | Lili Yang | Method for the generation of antigen-specific lymphocytes |
ES2601896T3 (es) * | 2004-11-24 | 2017-02-16 | Fred Hutchinson Cancer Research Center | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales |
JP2008539758A (ja) * | 2005-05-11 | 2008-11-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 抗原特異的t−細胞の急速な増大のための方法 |
PT1956080E (pt) | 2005-08-08 | 2011-12-30 | San Raffaele Centro Fond | Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória |
-
2009
- 2009-03-05 CN CN2009100792599A patent/CN101824400B/zh not_active Expired - Fee Related
- 2009-04-30 US US13/254,039 patent/US9080152B2/en not_active Expired - Fee Related
- 2009-04-30 WO PCT/CN2009/000481 patent/WO2010099637A1/zh active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102662054A (zh) * | 2012-05-10 | 2012-09-12 | 东南大学 | 一种同步检测特异性胸腺依赖性淋巴细胞数量和功能的方法 |
CN102662054B (zh) * | 2012-05-10 | 2014-08-13 | 东南大学 | 一种同步检测特异性胸腺依赖性淋巴细胞数量和功能的方法 |
Also Published As
Publication number | Publication date |
---|---|
US9080152B2 (en) | 2015-07-14 |
CN101824400B (zh) | 2012-08-08 |
US20120100180A1 (en) | 2012-04-26 |
WO2010099637A1 (zh) | 2010-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101824400B (zh) | 一种放大增殖抗原特异性t细胞的方法 | |
CN103898051B (zh) | 提高免疫反应性的方法 | |
CN105602992B (zh) | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 | |
CN107034237B (zh) | 一种car-nk细胞及其制备方法与应用 | |
CN106459914A (zh) | 经修饰的自然杀伤细胞及其用途 | |
CN103502439A (zh) | 用于抗原特异性t细胞增殖的方法 | |
CN105949316B (zh) | 抗EGFRvIII嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 | |
Cui et al. | Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells | |
CN105950664B (zh) | 一种靶向cd123的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 | |
CN105274053B (zh) | 一种高细胞毒活性的cik细胞的制备方法 | |
CN101386840A (zh) | Cd3-cd56+nk细胞高效扩增培养系统的构建方法 | |
CN108289909A (zh) | 用于产生工程改造的人原代血液树突细胞系的方法 | |
CN110305906B (zh) | 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞 | |
CN108884440A (zh) | 用于增强免疫疗法的抗肿瘤活性的间充质干细胞 | |
EA012520B1 (ru) | Способ получения цитотоксических лимфоцитов | |
CN106279432B (zh) | 一种vc-car分子及在清除hiv-1感染细胞中的应用 | |
Romain et al. | CD 34‐derived dendritic cells transfected ex vivo with HIV‐G ag m RNA induce polyfunctional T‐cell responses in nonhuman primates | |
CN105384826A (zh) | 表达嵌合抗原受体的脐血有核细胞及其应用 | |
CN103002915A (zh) | 抑制Treg细胞的方法和组合物 | |
CN110358734A (zh) | 以Tcm为主要效应成分的CAR-T制备方法及其应用 | |
CN102787097A (zh) | 经修饰的树突状细胞及包含该树突状细胞的疫苗 | |
CN109517798A (zh) | 一种嵌合cea抗原受体的nk细胞及其制备方法与应用 | |
Chondronasiou et al. | Improved induction of anti-melanoma T cells by adenovirus-5/3 fiber modification to target human DCs | |
CN107286246A (zh) | 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法 | |
CN104434973A (zh) | 一种强化细胞因子诱导的杀伤细胞功能的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANTONG BIOLOGICAL SCIENCE PARK DEVELOPMENT INVEST Free format text: FORMER OWNER: MICROBIOLOGY INST., CHINESE ACADEMY OF SCIENCES Effective date: 20130930 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100080 HAIDIAN, BEIJING TO: 226002 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130930 Address after: 226002, No. 118, city road, Gangzha District, Jiangsu, Nantong Patentee after: INSTITUTE OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES Address before: 100080 No. 13, north of Haidian District, Beijing, Zhongguancun Patentee before: Institute of Microbiology, Chinese Academy of Sciences |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160715 Address after: 100101 Beichen West Road, Beijing, No. 1 hospital, No. 3, No. Patentee after: Institute of Microbiology, Chinese Academy of Sciences Address before: 226002, No. 118, city road, Gangzha District, Jiangsu, Nantong Patentee before: INSTITUTE OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 Termination date: 20190305 |
|
CF01 | Termination of patent right due to non-payment of annual fee |